EndoPredict is the Only Test to Answer Three Critical Questions:
What is the 10-year Risk of Breast Cancer Coming Back?
What is the Patient’s Individualized Benefit from Chemotherapy?
Who is Unlikely to Benefit from Extended Endocrine Therapy?
EndoPredict is a next-generation breast cancer recurrence test that integrates tumor biology and pathology to accurately predict early and late (years 5-15) recurrence with an individualized absolute chemotherapy benefit.1-4
The first prognostic test to guide pre- and post-surgery treatment decisions across years 0-15.
An individualized absolute chemotherapy benefit for confident treatment decisions.
The only prognostic test that predicts distant recurrence up to 15 years to inform extended endocrine decisions.
In head-to-head studies, EndoPredict’s risk classification more accurately predicted patient observed risk than the leading competitor ‐ especially in years 5 to 10.3  

EndoPredict has broad insurance coverage, including Medicare and most commercial payers. For patients who encounter financial hardship, Myriad’s financial assistance programs can address a patient’s individual needs.
Learn more here: Myriad Promise.

EndoPredict is appropriate
for pre- and post-menopausal
women, diagnosed with ER+,
HER2− early-stage breast
cancer with either node-
negative or node-positive
disease (1- 3 nodes).2  
References: 1. Filipits M, Dubsky P, Rudas M, et al. Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years. Poster presented at: 41st Annual San Antonio Breast Symposium; December 5-9, 2018, San Antonio, TX. 2. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18)6012-6020. 3. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11): doi: 10.1093/jnci/djw149. 4. Sestak I, Martin M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. [published online ahead of print April 30, 2019]. https://doi.org/10.1007/s10549-019-05226-8.
Get Email Updates
Sample Report
Sample Report Sample Report Sample Report Sample Report Sample Report